patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_165519 | REC_0017501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 11.3 | 81 | female | 2 | 24 | 5.2 | 4 | alectinib 600 mg BID | 14.8 | false | MSI-H | 2026-03-15T05:36:02.310988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594112 | REC_0017502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 8.2 | 60 | female | 1 | 17 | 6.1 | 5 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.311855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677024 | REC_0017503 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.5 | 61 | female | 0 | 13 | 3.8 | 7 | alectinib 600 mg BID | 4.1 | true | MSS | 2026-03-15T05:36:02.316046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148262 | REC_0017504 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.3 | 67 | female | 1 | 18 | 3.4 | 0 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:36:02.317172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449420 | REC_0017505 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 14.3 | 63 | male | 0 | 16 | 4.6 | 0 | entrectinib 600 mg daily | 31.7 | false | MSS | 2026-03-15T05:36:02.318196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398880 | REC_0017506 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.7 | 61 | female | 1 | 70 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:36:02.319131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473926 | REC_0017507 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.7 | 69 | female | 1 | 16 | 4.2 | 1 | entrectinib 600 mg daily | 23.2 | false | MSI-H | 2026-03-15T05:36:02.319945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715982 | REC_0017508 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 9.6 | 69 | female | 1 | 10 | 5.8 | 1 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:36:02.320976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129341 | REC_0017509 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 11.9 | 73 | female | 1 | 16 | 7.1 | 1 | entrectinib 600 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:36:02.321775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332781 | REC_0017510 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 8.4 | 70 | female | 2 | 25 | 6.1 | 6 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:02.326780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180404 | REC_0017511 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.3 | 61 | male | 0 | 26 | 5.5 | 6 | sotorasib 960 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:02.327741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931045 | REC_0017512 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 31 | 3 | 71 | female | 1 | 16 | 4.5 | 0 | pembrolizumab 200 mg q3w | 21.9 | false | MSS | 2026-03-15T05:36:02.329156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881303 | REC_0017513 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 12.9 | 59 | female | 1 | 10 | 5 | 7 | pembrolizumab 200 mg q3w | 8 | false | MSI-H | 2026-03-15T05:36:02.330233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911679 | REC_0017514 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.1 | 68 | female | 1 | 12 | 6 | 2 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:02.331209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177884 | REC_0017515 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.5 | 82 | female | 1 | 6 | 6.1 | 8 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:02.332810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506330 | REC_0017516 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 17.4 | 59 | male | 0 | 19 | 3.5 | 5 | entrectinib 600 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:02.333856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986420 | REC_0017517 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.6 | 61 | female | 1 | 43 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 31.4 | true | MSS | 2026-03-15T05:36:02.334861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662077 | REC_0017518 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.7 | 65 | female | 1 | 16 | 5.8 | 1 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:02.335761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795186 | REC_0017519 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 18.1 | 76 | female | 1 | 9 | 5.8 | 1 | entrectinib 600 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:36:02.336737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606487 | REC_0017520 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9 | 73 | male | 1 | 12 | 5.9 | 6 | alectinib 600 mg BID | 13.5 | true | MSS | 2026-03-15T05:36:02.337626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366650 | REC_0017521 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.9 | 85 | female | 2 | 4 | 5.3 | 4 | entrectinib 600 mg daily | 4.5 | false | MSI-H | 2026-03-15T05:36:02.344503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318460 | REC_0017522 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 15.7 | 72 | female | 1 | 29 | 5.2 | 0 | osimertinib 80 mg daily | 32.1 | false | MSI-H | 2026-03-15T05:36:02.345325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274539 | REC_0017523 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.6 | 66 | female | 1 | 60 | 7.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:36:02.346125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708795 | REC_0017524 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8 | 77 | female | 2 | 6 | 3.9 | 1 | sotorasib 960 mg daily | 23.5 | true | MSS | 2026-03-15T05:36:02.346872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246045 | REC_0017525 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.3 | 68 | female | 1 | 10 | 5 | 5 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:02.347879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214858 | REC_0017526 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.3 | 63 | female | 0 | 16 | 5.7 | 7 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:02.349022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715675 | REC_0017527 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 13.1 | 54 | male | 0 | 7 | 7.6 | 6 | osimertinib 80 mg daily | 6.4 | true | MSS | 2026-03-15T05:36:02.349823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232510 | REC_0017528 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 11.7 | 63 | female | 0 | 18 | 5.7 | 1 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:02.350665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640002 | REC_0017529 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.3 | 66 | female | 1 | 17 | 6.4 | 2 | sotorasib 960 mg daily | 21.5 | true | MSI-H | 2026-03-15T05:36:02.351558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467103 | REC_0017530 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.9 | 58 | male | 1 | 21 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:36:02.352629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201777 | REC_0017531 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 10 | 71 | female | 2 | 12 | 5.4 | 5 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:36:02.353497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723670 | REC_0017532 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4 | 57 | female | 0 | 59 | 5.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.4 | false | MSS | 2026-03-15T05:36:02.354326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858765 | REC_0017533 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 8.2 | 54 | male | 0 | 50 | 4.6 | 2 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:36:02.355157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401538 | REC_0017534 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 5.9 | 60 | female | 1 | 12 | 6.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 43.7 | false | MSS | 2026-03-15T05:36:02.356542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420643 | REC_0017535 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.7 | 78 | female | 1 | 10 | 6.2 | 6 | entrectinib 600 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:36:02.357683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146855 | REC_0017536 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 7.6 | 43 | female | 0 | 16 | 5.9 | 7 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:02.358847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300246 | REC_0017537 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.4 | 61 | female | 1 | 33 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:36:02.359916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875197 | REC_0017538 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11 | 63 | female | 1 | 17 | 4.5 | 2 | osimertinib 80 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:36:02.362633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359497 | REC_0017539 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 14.3 | 60 | male | 0 | 3 | 5.5 | 1 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:36:02.364392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167055 | REC_0017540 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.2 | 59 | male | 1 | 52 | 5.6 | 4 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:36:02.365304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171592 | REC_0017541 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.5 | 68 | female | 0 | 7 | 3.2 | 1 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:36:02.366293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526698 | REC_0017542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.7 | 73 | female | 1 | 17 | 5.2 | 6 | alectinib 600 mg BID | 16.7 | false | MSI-H | 2026-03-15T05:36:02.367240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779935 | REC_0017543 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 4.4 | 72 | female | 1 | 7 | 4 | 2 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:36:02.368492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297073 | REC_0017544 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 35 | 7.7 | 47 | female | 0 | 19 | 4.9 | 5 | pembrolizumab 200 mg q3w | 14.9 | false | MSS | 2026-03-15T05:36:02.370865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225138 | REC_0017545 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.6 | 62 | female | 1 | 14 | 6.4 | 1 | entrectinib 600 mg daily | 39.5 | true | MSS | 2026-03-15T05:36:02.371751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866243 | REC_0017546 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 7.5 | 60 | female | 0 | 17 | 5.5 | 1 | alectinib 600 mg BID | 18.3 | false | MSS | 2026-03-15T05:36:02.372880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713287 | REC_0017547 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 6.8 | 71 | female | 1 | 14 | 5.2 | 6 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:36:02.373954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209373 | REC_0017548 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 21.5 | 85 | female | 2 | 20 | 4.2 | 7 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:02.375032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558821 | REC_0017549 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.2 | 79 | female | 2 | 61 | 4.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:36:02.376192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589104 | REC_0017550 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13 | 68 | female | 2 | 17 | 4.1 | 1 | entrectinib 600 mg daily | 25 | true | MSS | 2026-03-15T05:36:02.382972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895151 | REC_0017551 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5 | 80 | female | 3 | 57 | 4.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:36:02.398205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591659 | REC_0017552 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.4 | 77 | female | 1 | 8 | 5.6 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.399042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205560 | REC_0017553 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.8 | 71 | male | 1 | 13 | 6.1 | 3 | sotorasib 960 mg daily | 9 | true | MSI-H | 2026-03-15T05:36:02.399878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731960 | REC_0017554 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 11 | 10.3 | 69 | male | 0 | 15 | 3.5 | 7 | pembrolizumab 200 mg q3w | 16.5 | true | MSS | 2026-03-15T05:36:02.400804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304539 | REC_0017555 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.2 | 66 | female | 1 | 47 | 5.5 | 9 | pembrolizumab 200 mg q3w | 13 | true | MSS | 2026-03-15T05:36:02.401691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409407 | REC_0017556 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.3 | 69 | female | 1 | 17 | 3.2 | 2 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:36:02.402555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942290 | REC_0017557 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 8.9 | 74 | female | 1 | 10 | 3.6 | 7 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:36:02.403431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765651 | REC_0017558 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.6 | 57 | male | 0 | 27 | 4.4 | 4 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:02.404402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148338 | REC_0017559 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 16.2 | 67 | female | 0 | 8 | 4.5 | 0 | osimertinib 80 mg daily | 31.8 | true | MSI-H | 2026-03-15T05:36:02.405331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453752 | REC_0017560 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12 | 73 | female | 0 | 17 | 6.8 | 3 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:36:02.406451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331935 | REC_0017561 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 13.5 | 73 | female | 1 | 14 | 4.6 | 2 | sotorasib 960 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:02.407595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516595 | REC_0017562 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 13.1 | 51 | male | 0 | 2 | 4.2 | 1 | osimertinib 80 mg daily | 23.3 | false | MSI-H | 2026-03-15T05:36:02.416837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517032 | REC_0017563 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 5.5 | 73 | female | 1 | 43 | 7.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:02.417727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115997 | REC_0017564 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 16.3 | 69 | male | 1 | 6 | 4.6 | 1 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:36:02.419083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832556 | REC_0017565 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 20 | 10.7 | 68 | female | 0 | 8 | 3.8 | 0 | entrectinib 600 mg daily | 48.5 | false | MSI-H | 2026-03-15T05:36:02.420291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168646 | REC_0017566 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.8 | 68 | female | 0 | 15 | 5.2 | 7 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:36:02.422050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368686 | REC_0017567 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.8 | 64 | female | 0 | 14 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.5 | true | MSS | 2026-03-15T05:36:02.423221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833544 | REC_0017568 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 1.5 | 72 | female | 1 | 36 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20 | false | MSS | 2026-03-15T05:36:02.424398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996475 | REC_0017569 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.9 | 70 | female | 2 | 23 | 5 | 6 | osimertinib 80 mg daily | 16.9 | false | MSI-H | 2026-03-15T05:36:02.425426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221576 | REC_0017570 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 7 | 79 | male | 2 | 4 | 3.8 | 2 | pembrolizumab 200 mg q3w | 29.2 | false | MSS | 2026-03-15T05:36:02.426574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813130 | REC_0017571 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 3.5 | 54 | female | 0 | 16 | 6 | 2 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:36:02.427360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121684 | REC_0017572 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.6 | 72 | female | 1 | 20 | 5.5 | 5 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:02.428189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368523 | REC_0017573 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.3 | 63 | male | 1 | 15 | 3.5 | 8 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:36:02.428971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296833 | REC_0017574 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.8 | 51 | male | 0 | 11 | 7.8 | 2 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:36:02.429762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331765 | REC_0017575 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8 | 65 | female | 0 | 16 | 6 | 6 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:36:02.430523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361144 | REC_0017576 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 19.1 | 53 | female | 0 | 8 | 3.6 | 6 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:02.431324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570650 | REC_0017577 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 8.8 | 60 | female | 1 | 63 | 5.4 | 2 | pembrolizumab 200 mg q3w | 26.9 | false | MSS | 2026-03-15T05:36:02.432990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348880 | REC_0017578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.4 | 64 | male | 1 | 18 | 7.2 | 7 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:36:02.435793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493225 | REC_0017579 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.5 | 57 | female | 1 | 11 | 3.9 | 7 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:02.436707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784625 | REC_0017580 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 5 | 61 | female | 1 | 16 | 4 | 1 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:02.437649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536096 | REC_0017581 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 5.7 | 77 | female | 1 | 21 | 5.5 | 0 | osimertinib 80 mg daily | 41.9 | false | MSS | 2026-03-15T05:36:02.440534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899008 | REC_0017582 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 17.1 | 74 | female | 3 | 11 | 5.6 | 1 | osimertinib 80 mg daily | 26.8 | false | MSS | 2026-03-15T05:36:02.442677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327076 | REC_0017583 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10 | 74 | female | 2 | 17 | 7.3 | 1 | entrectinib 600 mg daily | 7.8 | true | MSS | 2026-03-15T05:36:02.443692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492470 | REC_0017584 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.9 | 69 | male | 1 | 15 | 4.1 | 0 | alectinib 600 mg BID | 23.5 | true | MSS | 2026-03-15T05:36:02.444648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600141 | REC_0017585 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.4 | 81 | female | 2 | 60 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.7 | false | MSS | 2026-03-15T05:36:02.445506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533774 | REC_0017586 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.5 | 60 | male | 1 | 71 | 7.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.9 | false | MSS | 2026-03-15T05:36:02.446358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968961 | REC_0017587 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.6 | 63 | female | 1 | 57 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.2 | true | MSS | 2026-03-15T05:36:02.447209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450546 | REC_0017588 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 7.4 | 57 | male | 0 | 22 | 3.7 | 1 | pembrolizumab 200 mg q3w | 26.8 | true | MSS | 2026-03-15T05:36:02.448751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584480 | REC_0017589 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.2 | 63 | male | 1 | 10 | 5 | 1 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:36:02.449676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708654 | REC_0017590 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 30 | 4.9 | 66 | female | 1 | 63 | 6.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 45.6 | false | MSS | 2026-03-15T05:36:02.452872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784119 | REC_0017591 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.8 | 66 | female | 1 | 29 | 3.4 | 5 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:36:02.453704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910768 | REC_0017592 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 9.6 | 74 | female | 1 | 18 | 4.6 | 2 | sotorasib 960 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:02.454579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766216 | REC_0017593 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 11.4 | 65 | male | 0 | 16 | 2.5 | 2 | osimertinib 80 mg daily | 24.7 | false | MSS | 2026-03-15T05:36:02.456299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212038 | REC_0017594 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.6 | 67 | female | 1 | 7 | 3.9 | 4 | entrectinib 600 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:02.457459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974739 | REC_0017595 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.1 | 75 | female | 1 | 36 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:36:02.458487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821800 | REC_0017596 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 5.2 | 72 | male | 1 | 17 | 5.8 | 7 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:02.461025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785082 | REC_0017597 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.9 | 60 | male | 0 | 19 | 8 | 2 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:36:02.461934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736688 | REC_0017598 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.9 | 74 | female | 2 | 46 | 7 | 3 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:36:02.462709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583987 | REC_0017599 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.3 | 80 | female | 2 | 9 | 3.6 | 6 | alectinib 600 mg BID | 9.3 | false | MSI-H | 2026-03-15T05:36:02.464535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798269 | REC_0017600 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.1 | 68 | female | 1 | 16 | 3.5 | 6 | entrectinib 600 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:36:02.465413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.